Key result
CYP2C19 point-of-care testing identified 38% of stroke and TIA patients as intermediate or poor metabolizers, resulting in a change to alternative tailored secondary prevention.
Why the study?
Over 25% of the population is resistant to clopidogrel due to reduced CYP2C19 enzyme activity, rendering it less effective or ineffective for stroke secondary prevention.
Does CYP2C19 genotype point-of-care testing identify stroke patients requiring alternative secondary prevention therapy?
Observational (n=76)
Does CYP2C19 genotype point-of-care testing identify stroke patients requiring alternative secondary prevention therapy?
CYP2C19 point-of-care testing in stroke patients identifies a significant proportion (38%) with reduced clopidogrel metabolism, enabling rapid transition to alternative antiplatelet therapies like ticagrelor.
May enable tailored antiplatelet therapy after stroke; leaves open effects on recurrent events pending randomized trials.**[[1]](https://www.phgfoundation.
Background and aims Clopidogrel is a widely used drug for stroke secondary prevention following ischemic stroke and TIA. Over 25 % of the population is resistant to Clopidogrel due to reduced CYP2C19 enzyme activity. It makes Clopidogrel less effective or completely ineffective for secondary prevention. Rapid point-of-care testing (POCT) of Clopidogrel resistance identifies patients who need an alternative tailored treatment. Methods CYP2C19 POCT was initially implemented for a group of following patients before starting or already on stroke secondary prevention with Clopidogrel: POCT was performed from March 2025 to January 2026. To detect the six most common alleles (*2, *3, *4, *8, *17 and *35) the Genedrive System was used. Based on the CYP2C19 genotype, patients were classified as normal, rapid, ultra-rapid, intermediate and poor metabolizers. Multidisciplinary team discussed the genotype results, metabolism, likely phenotype, implications of the results and made recommendations for further personalized management. Results A total of 76 patients were tested. The cohort included 34 young stroke patients (45 %). 26 Normal metabolisers (*1/*1), 18 rapid (*1/*17), 3 ultra-rapid (*17/*17), 21 intermediate (*1/*2, *2/*17), and 8 poor (*2/*2) metabolizers were detected. 29 patients (38 %), intermediate and poor metabolisers, required a change to alternative tailored stroke secondary prevention. 19 of these patients were started on Ticagrelor as an alternative. Conclusions CYP2C19 POCT is a fast and efficient method for precise stroke secondary prevention. Conflict of interest Nothing to disclose
No takes yet. Share an insight, caveat, or question.
Líčeník et al. (2026) conducted an observational in Ischemic stroke and TIA (n=76). CYP2C19 point-of-care testing was evaluated on Change to alternative tailored stroke secondary prevention. CYP2C19 point-of-care testing identified 38% of stroke and TIA patients as intermediate or poor metabolizers, resulting in a change to alternative tailored secondary prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: